title: Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.
abstract: Female nonobese diabetic (NOD) mice develop spontaneous autoimmune sialadenitis and loss of salivary flow, and are a widely used model of Sjögren's syndrome. We examined the feasibility of local salivary gland immunomodulatory gene delivery to alter these sequelae in NOD mice. We constructed recombinant adeno-associated virus (rAAV) vectors encoding either human interleukin 10 (rAAVhIL-10) or beta-galactosidase (rAAVLacZ, control vector). Mice received rAAVhIL-10 or rAAVLacZ by retrograde submandibular ductal instillation either at age 8 weeks (early, before onset of sialadenitis), or at 16 weeks (late, after onset of sialadenitis). As a systemic treatment control, separate mice received intramuscular delivery of rAAVhIL-10 at each time point. Both submandibular and intramuscular delivery of vector led to low circulating levels of hIL-10. After submandibular administration of rAAVhIL-10, salivary flow rates at 20 weeks for both the early and late treatment groups were significantly higher than for both rAAVLacZ-administered and untreated mice. Systemic delivery of rAAVhIL-10 led to improved salivary flow in the late treatment group. Inflammatory infiltrates in submandibular glands, however, were significantly reduced only in mice receiving rAAVhIL-10 locally in the salivary gland compared with mice receiving this vector intramuscularly, or rAAVLacZ or no treatment. In addition, after submandibular rAAVhIL-10 delivery, NOD mice exhibited significantly lower blood glucose, and higher serum insulin, levels than all other groups, indicating some systemic benefit of this treatment. These studies show that expression of hIL-10 by rAAV vectors can have disease-modifying effects in the salivary glands of NOD mice, and suggest that local immunomodulatory gene transfer may be useful for managing the salivary gland pathology in Sjögren's syndrome.
authors: Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
authors: Marc R
authors: MR
authors: Kok
authors: Seichii
authors: S
authors: Yamano
authors: Beatrijs M
authors: BM
authors: Lodde
authors: Jianghua
authors: J
authors: Wang
authors: Ross I
authors: RI
authors: Couwenhoven
authors: Shoshana
authors: S
authors: Yakar
authors: Antony
authors: A
authors: Voutetakis
authors: Derek
authors: D
authors: Leroith
authors: Michael
authors: M
authors: Schmidt
authors: Sandra
authors: S
authors: Afione
authors: Stanley R
authors: SR
authors: Pillemer
authors: Marjorie T
authors: MT
authors: Tsutsui
authors: Paul P
authors: PP
authors: Tak
authors: John A
authors: JA
authors: Chiorini
authors: Bruce J
authors: BJ
authors: Baum
mesh_terms: D000818:Animals; D002460:Cell Line; D018076:DNA, Complementary / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics*; D004195:Disease Models, Animal; D005260:Female; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D016688:Mice, Inbred NOD; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012469:Salivary Glands / Q000378:metabolism; D012859:Sjogren's Syndrome / Q000628:therapy*; D013997:Time Factors
chemical_list: D018076:DNA, Complementary; D016753:Interleukin-10